亚海生物科技有限公司
YA HAI BIOTECHNOLOGY LTD

Product Search
Online Service
 工作时间
周一至周五 :8:30-17:30
周六至周日 :9:00-17:00
Contact Information

联系人:Amos

电 话(Tel):+8615323376147

邮 箱(E-Mail):yhgenedit@outlook.com

地   址:深圳市龙岗区1983创意小镇

Address:1983 Creative Town,LongGang District,ShenZhen City


联系人:Lucas

电 话(Tel):+8613316427610

地   址:深圳市龙岗区1983创意小镇

Address:1983 Creative Town,LongGang District,ShenZhen City


地   址:广州市南沙区南沙街海裕二街2号1栋1917房

Address:Room 1917,Building 1,HaiYu Second Street,NanSha District,GuangZhou City

产品详情

PD-L1抗体试剂Programmed Death-Ligand 1 Antibody Reagent

Programmed death-ligand 1 (PD-L1) antibody is a type of reagent that is used in medical research and clinical practice to detect and block the PD-L1 protein.
PD-L1 is a protein that is found on the surface of some cells in the body, including cancer cells, and is known to help them evade the immune system's response.
Product Details
用途Purpose 非小细胞肺癌Non-small Cell Lung Cancer 样本类型Sample Type 石蜡包埋组织切片 Paraffim-Embedded Tissue Section
储存条件Storage Condition 2-8℃保存,不得冻存/2-8℃ preservation,not freezing cryopreservation 货期Deliver Time 现货 Spot Goods
包装规格Package Specification 1.5ml/bottle;3ml/bottle;5ml/bottle

Programmed death-ligand 1 (PD- L1) antibody is a type of reagent that is used in medical research

and clinical practice to detect and block the PD-L1 protein. PD-L1 is a protein that is found

on the surface of some cells in the body, including cancer cells, and is known to help them evade

the immune system's response.

PD-L1 antibodies work by binding to the PD-L1 protein and preventing it from interacting with its

receptor on immune cells, which can then stimulate the immune system to attack cancer cells. This

approach is known as immune checkpoint blockade therapy and has shown promise in treating certain

types of cancer, such as melanoma, lung cancer, and bladder cancer.

PD-L1 antibodies are also used in diagnostic tests to determine the level of PD-L1 expression in

tumor cells. This information can help doctors determine which patients are more likely to respond

to immune checkpoint blockade therapy.